VistaGen Therapeutics Inc (NASDAQ: VTGN) stock closed at $4.15 on 12/4/23 after a major increase of 13.7%. Moreover, unusually high trading volume at 194% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and has risen 15.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, VTGN is expected to be a modest Value Eraser.
VistaGen Therapeutics has a current Value Trend Rating of D (Negative). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. VistaGen Therapeutics has a poor Appreciation Score of 15 but a slightly positive Power Rating of 63, with the Negative Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment